GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Silo Pharma Inc.
Silo Pharma is a biotech company developing psychedelic drugs for the treatment of neurological disorders. Its stock price is a venture capital bet on the legalization and medical use of these substances.
Share prices of companies in the market segment - Pharma psycho
Silo Pharma is a biopharmaceutical company developing drugs based on psychedelics and other innovative compounds for the treatment of neurological disorders. We have classified it in the Pharma: Psychology category. The chart below shows the dynamics of this new and promising pharmaceutical segment.
Broad Market Index - GURU.Markets
Silo Pharma is a biopharmaceutical company developing psychedelic-based drugs and other innovative treatments for neurological disorders. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SILO - Daily change in the company's share price Silo Pharma Inc.
Silo Pharma, Inc.'s daily price change reflects the high volatility inherent in biotech companies working with psychedelics. This metric measures sensitivity to news about clinical trials and regulatory changes.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Silo Pharma is a biopharmaceutical company researching the therapeutic use of psychedelics such as psilocybin. This is a highly speculative and volatile sector. The chart below reflects average fluctuations in this niche, serving as an indicator of risks and investor expectations.
Daily change in the price of a broad market stock, index - GURU.Markets
Silo Pharma is a biotech company developing psychedelic-based drugs. News of clinical trials in this cutting-edge field triggers sharp stock price movements, which, in turn, contribute to the overall "noise" and market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Silo Pharma Inc.
Silo Pharma, Inc.'s year-over-year performance is a story of psychedelic drug development. Its 12-month market cap depends entirely on progress in preclinical and clinical research. The success of its approaches, including the use of ketamine to treat fibromyalgia, could be a breakthrough in this innovative field of medicine.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Silo Pharma, Inc. is a biotech company developing psychedelic-based drugs. Its stock price is entirely speculative and based on investor confidence in the future potential of this innovative, yet controversial, approach to medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Silo Pharma, a biopharmaceutical company researching psychedelic drugs for the treatment of neurological disorders, is working in a revolutionary and controversial field. Its year-over-year market capitalization reflects the evolving attitudes of society and regulators toward psychedelics. It's a high-risk, but potentially groundbreaking, venture.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Silo Pharma Inc.
Silo Pharma is a biotech company developing psychedelic therapeutics. Its monthly performance is entirely dependent on progress in its clinical programs. News about research results and regulatory changes are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Silo Pharma is a biotech company developing new psychedelic-based therapeutics for the treatment of mental disorders and neurological diseases. This is a high-risk field. The psychopharmaceutical sector chart reflects both the enormous potential and the regulatory hurdles facing companies like Silo.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Silo Pharma is a biotech company researching psychedelics like psilocybin for the treatment of mental disorders. Its stock is highly speculative, depending entirely on legislative changes and clinical trial results. It has no connection to the broader market; it's betting on legalization and a medical breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Silo Pharma Inc.
Silo Pharma, a biotech company researching psychedelics for the treatment of neurological disorders, operates at the intersection of science and evolving legislation. Its weekly stock price reflects both progress in research and news of the decriminalization of these substances for medical use.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Silo Pharma is a biotech company developing psychedelic drugs for the treatment of mental disorders such as depression and PTSD. Its shares are extremely sensitive to news and regulatory changes. The chart clearly shows how its performance differs from traditional pharmaceuticals.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Silo Pharma is a biotech company developing psychedelic drugs. Its shares are driven by news of legalization and trial results. The chart will show how its performance is detached from the broader market and how it operates according to the industry's own highly volatile laws.
Market capitalization of the company, segment and market as a whole
SILO - Market capitalization of the company Silo Pharma Inc.
Silo Pharma's market capitalization reflects investors' assessment of its strategy for developing psychedelic drugs. The chart shows how the market values its research into the use of substances like psilocybin and ketamine to treat neurological and psychiatric disorders. Its high volatility reflects both the potential and regulatory risks of this emerging field.
SILO - Share of the company's market capitalization Silo Pharma Inc. within the market segment - Pharma psycho
Silo Pharma is a biopharmaceutical company focused on developing psychedelic drugs for the treatment of mental disorders. Its market share is small, but it is at the forefront of the "psychedelic renaissance." Its market cap is a bet on its scientific research and potential regulatory changes.
Market capitalization of the market segment - Pharma psycho
Below is a chart showing the total value of the entire pharmaceutical sector focused on treating mental disorders. For Silo Pharma, which works with psychedelics, this line is a map of the scientific revolution. Its growth demonstrates how investors are beginning to believe in the therapeutic potential of these once-banned substances.
Market capitalization of all companies included in a broad market index - GURU.Markets
Silo Pharma is a company developing new therapeutic approaches using psychedelic drugs. Its market capitalization is another bet on a medical revolution in psychiatry. This represents the share of the overall market occupied by psychedelic research.
Book value capitalization of the company, segment and market as a whole
SILO - Book value capitalization of the company Silo Pharma Inc.
Silo Pharma is a biopharmaceutical company developing new treatments using psychedelics. Its book value is the financial resources it has available for preclinical research and partnerships. How has this innovative scientific capital evolved? The chart below shows.
SILO - Share of the company's book capitalization Silo Pharma Inc. within the market segment - Pharma psycho
Silo Pharma, Inc. develops new therapeutic approaches using psychedelics. Its scientific work requires a resource base: a laboratory for the research and development of new formulations for targeted delivery. The chart shows the company's share of the physical R&D infrastructure for this cutting-edge field.
Market segment balance sheet capitalization - Pharma psycho
Silo Pharma is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. Silo focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Silo Pharma's assets aren't factories, but a unique business model: the company licenses promising psychedelic drugs from universities and then funds their preclinical research. Its book value reflects the value of these licenses and the capital for their development. The chart illustrates this scale.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Silo Pharma Inc.
Silo Pharma is a biopharmaceutical company developing psychedelic-based drugs for the treatment of mental disorders. Its market capitalization is a speculative bet on the legalization and medical use of these substances.
Market to book capitalization ratio in a market segment - Pharma psycho
Silo Pharma is a company developing psychedelic drugs. This is a highly speculative field. Its market valuation on this chart reflects investors' pure faith that psychedelics will become mainstream medicine, despite the enormous regulatory barriers.
Market to book capitalization ratio for the market as a whole
Silo Pharma is a biotech company researching psychedelics for the treatment of mental disorders. Its valuation is pure speculation on future success in a highly promising but risky field. This chart helps assess the market's willingness to accept risk when investing in revolutionary, yet unproven, approaches to medicine.
Debts of the company, segment and market as a whole
SILO - Company debts Silo Pharma Inc.
Silo Pharma, a biopharmaceutical company researching psychedelics for the treatment of neurological disorders, is in its early stages. It relies entirely on external funding for its preclinical and early clinical trials. This chart shows the costs of working at the forefront of neuroscience and pharmaceuticals.
Market segment debts - Pharma psycho
Silo Pharma is an early-stage biopharmaceutical company focused on the use of psychedelics to treat mental disorders such as depression and PTSD. The chart shows how the company is raising capital to fund its preclinical and early clinical trials in this cutting-edge, yet risky, area of medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Silo Pharma Inc.
Silo Pharma is a biotech company developing new treatments based on psychedelics such as psilocybin. Research in this cutting-edge but highly regulated field is extremely expensive. This chart shows how the company uses debt to finance its high-risk but potentially breakthrough clinical programs.
Market segment debt to market segment book capitalization - Pharma psycho
Silo Pharma is a biopharmaceutical company developing psychedelic drugs for the treatment of neurological disorders. This is a highly risky but potentially disruptive field. This chart shows how the company finances its unique research, comparing its debt structure to the broader biotech landscape.
Debt to book value of all companies in the market
Silo Pharma is a biotech company researching the use of psychedelics like psilocybin to treat neurological disorders. This is a cutting-edge, but high-risk, field. How heavily is the company reliant on debt? This chart of total market debt helps assess the riskiness of its financial strategy.
P/E of the company, segment and market as a whole
P/E - Silo Pharma Inc.
Silo Pharma is a biopharmaceutical company focused on developing new treatments using psychedelic compounds. This chart shows speculative investor interest in this area. The valuation is highly volatile and depends on research progress and regulatory changes.
P/E of the market segment - Pharma psycho
Silo Pharma is a biopharmaceutical company developing new therapeutic approaches, including the use of psychedelics, to treat neurological and mental health disorders. This chart illustrates the average valuation in the psychopharmaceutical sector, where investors perceive both the high potential and risks associated with psychedelic medicine.
P/E of the market as a whole
Silo Pharma, Inc. is a biopharmaceutical company focused on developing new treatments for mental disorders such as depression and PTSD using psychedelic compounds. This chart reflects overall investor interest in the psychedelics sector. It helps understand whether SILO's valuation reflects speculative interest in this emerging field or general trends in biotech.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Silo Pharma Inc.
Silo Pharma is a biopharmaceutical company developing new therapeutics based on psychedelics, such as psilocybin and ketamine, for the treatment of neurological disorders. This chart reflects investor speculative expectations regarding the future legalization and medical use of psychedelic drugs.
%20P%2FE%20Silo%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Silo-Pharma-Inc.&v=1772678614348 "Chart of the company's future (projected) P/E Silo Pharma Inc.")
Future (projected) P/E of the market segment - Pharma psycho
Silo Pharma is a biopharmaceutical company researching the use of psychedelics such as psilocybin and ketamine to treat mental disorders. The chart reflects expectations for future profits in the sector. It helps understand the extent to which investors believe in a therapeutic breakthrough and the future legalization of these substances for medical use.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772678614362 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Silo Pharma is a biotech company focused on developing new treatments using psychedelic drugs, such as psilocybin. This sector is in its early stages and carries significant regulatory risks. This risk appetite chart is a barometer of investor willingness to invest in such bold and controversial medical advances.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772678614396 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Silo Pharma Inc.
Silo Pharma, Inc. is a development-stage biopharmaceutical company exploring the use of psychedelics such as psilocybin for the treatment of neurological disorders and post-traumatic stress disorder (PTSD). Financial metrics reflect R&D expenditures. This chart shows investments in the cutting-edge yet complex field of psychiatry.
Profit of companies in the market segment - Pharma psycho
Silo Pharma, Inc. is a biopharmaceutical company developing novel therapeutics based on psychedelics such as psilocybin and ketamine for the treatment of mental disorders. This chart reflects the financial health of the nascent psychedelic medicine sector, where research is opening up new avenues for the treatment of depression and PTSD.
Overall market profit
Silo Pharma, Inc. is a biopharmaceutical company developing medications for the treatment of mental disorders, including psychedelics. Its success depends on the results of clinical trials and regulatory changes. This innovative sector does not correlate with general economic cycles, as can be seen in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Silo Pharma Inc.
Silo Pharma is a biopharmaceutical company focused on developing new therapeutic agents using psychedelics, such as psilocybin, to treat neurological disorders. Future revenue depends on clinical success and regulatory changes for these compounds. This graph reflects expectations for the resurgence of psychedelic medicine.
%20profit%20of%20the%20company%20Silo%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Silo-Pharma-Inc.&v=1772678614594 "Graph of future (projected) profit of the company Silo Pharma Inc.")
Future (predicted) profit of companies in the market segment - Pharma psycho
Silo Pharma is a biopharmaceutical company developing new treatments using psychedelic compounds, such as psilocybin. The company is exploring their potential for treating depression and Parkinson's disease. This chart shows revenue projections for the psychopharmaceutical sector, providing context for evaluating Silo Pharma's cutting-edge research.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772678614638 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Silo Pharma, Inc. is a biopharmaceutical company developing psychedelic drugs for the treatment of mental disorders. Its success depends on clinical trials and regulatory changes. This revenue expectation schedule impacts the availability of venture capital for funding in such an innovative but risky field.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772678614647 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Silo Pharma Inc.
Silo Pharma is a biopharmaceutical company developing psychedelic drugs for the treatment of mental disorders. There is no revenue at the research stage. This chart reflects investors' confidence in the therapeutic potential of psychedelics and the company's ability to bring its drugs through clinical trials.
P/S market segment - Pharma psycho
Silo Pharma is a biopharmaceutical company developing new treatments using psychedelics such as psilocybin and ketamine for mental disorders, post-traumatic stress disorder, and Parkinson's disease. This chart shows the average revenue estimate for the sector, helping to gauge the market's perception of the future of psychedelic medicine.
P/S of the market as a whole
Silo Pharma is a biopharmaceutical company developing psychedelic drugs for the treatment of mental disorders such as depression and PTSD. This chart shows that the valuation of companies in this innovative but risky field is based on expectations of legalization and clinical success, not on current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Silo Pharma Inc.
Silo Pharma is a biopharmaceutical company developing new therapeutics using psychedelic compounds such as psilocybin. Its revenue valuation is crucial for the company, reflecting investor expectations for the success of its research and the changing regulatory environment that could make psychedelics a legitimate treatment for mental disorders.
%20P%2FS%20Silo%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Silo-Pharma-Inc.&v=1772678614787 "The graph of the company's future (projected) P/S Silo Pharma Inc.")
Future (projected) P/S of the market segment - Pharma psycho
Silo Pharma is a biopharmaceutical company developing new treatments based on psychedelics and other innovative compounds for psychiatric disorders. This chart shows how investors estimate the company's future earnings compared to the pharmaceutical sector. It demonstrates the market's confidence in the potential of psychedelic medicine and Silo Pharma's scientific developments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772678614872 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Silo Pharma is a biopharmaceutical company developing new therapeutics using psychedelic compounds for the treatment of neurological disorders and post-traumatic stress disorder (PTSD). This market forecast chart reflects growing investor interest in psychedelic medicine as a potentially breakthrough field.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772678614914 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Silo Pharma Inc.
The graph illustrates the financial activity of Silo Pharma, a biopharmaceutical company developing new treatments using psychedelic compounds for mental disorders. Being in the research stage, the company has no commercial revenue. Its cash flows are related to R&D expenses.
Sales of companies in the market segment - Pharma psycho
Silo Pharma is a biopharmaceutical company focused on developing new treatments using psychedelic compounds such as psilocybin and ketamine. Being in the development stage, it does not yet have revenue. Its future revenue depends on the success of its research in mental health and neuroscience.
Overall market sales
Silo Pharma, Inc. is a biopharmaceutical company researching the use of psychedelics, such as psilocybin, to treat mental disorders. The company operates in an innovative and rapidly developing field. This overall economic graph does not reflect the dynamics of this sector, whose growth is driven by scientific research and changing public and regulatory attitudes.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Silo Pharma Inc.
Silo Pharma is a biopharmaceutical company focused on developing new treatments for mental disorders such as PTSD and depression using psychedelic compounds and other innovative approaches. Future revenue is dependent on the success of clinical trials. The chart reflects analyst expectations for the potential of these new therapeutic modalities.
%20sales%20of%20the%20company%20Silo%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Silo-Pharma-Inc.&v=1772678615057 "Schedule of future (projected) sales of the company Silo Pharma Inc.")
Future (projected) sales of companies in the market segment - Pharma psycho
Silo Pharma is a biotech company developing psychedelic-based drugs for the treatment of mental disorders. This chart shows the forecast for the CNS drug market. Is legalization and growth expected in the psychedelic therapy market? This reflects the potential of this innovative field of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772678615106 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Silo Pharma is a biopharmaceutical company developing psychedelic drugs for the treatment of mental disorders. Its success depends on regulatory changes, clinical trial results, and public acceptance. This overall economic activity graph does not address these specific drivers, which will determine the future of the entire psychedelics industry.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772678615129 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Silo Pharma Inc.
Silo Pharma is a biopharmaceutical company developing new treatments for mental disorders using psychedelics, such as psilocybin. This chart reflects its financial performance at the preclinical stage. Profitability is a distant goal, dependent on successfully navigating the complex regulatory landscape and demonstrating the therapeutic value of its approaches.
Market segment marginality - Pharma psycho
Silo Pharma, Inc. is a biopharmaceutical company developing novel therapeutics, including psychedelics, for the treatment of neurological disorders. This chart reflects its financial position at the R&D stage, where profitability is a future goal dependent on the success of clinical trials and the changing regulatory landscape.
Market marginality as a whole
Silo Pharma, Inc. is a biotech company researching psychedelic drugs for the treatment of mental disorders. It operates in an innovative but regulatoryly complex field. This total return chart reflects investor appetite for high-risk projects, which increases during periods of economic stability.
Employees in the company, segment and market as a whole
Number of employees in the company Silo Pharma Inc.
Silo Pharma is a biotech company working on new ways to deliver psychedelic drugs for the treatment of mental disorders. Its small, virtual team manages research, collaborating with universities. This graph shows a very compact structure, typical for startups that outsource most of their R&D.
Share of the company's employees Silo Pharma Inc. within the market segment - Pharma psycho
Silo Pharma is a biotech company developing psychedelic drugs for the treatment of mental disorders. This is a cutting-edge and controversial field, requiring a team of scientists and clinical trial specialists. This graph shows the company's market share, reflecting its research ambitions in a new and rapidly growing pharmaceutical niche.
Number of employees in the market segment - Pharma psycho
Silo Pharma is a biopharmaceutical company exploring new therapeutic applications for psychedelic compounds such as psilocybin and ketamine for the treatment of mental disorders. The chart shows employment in the psychopharmaceutical sector. Silo Pharma is at the forefront of the "psychedelic renaissance" in medicine.
Number of employees in the market as a whole
Silo Pharma is a biopharmaceutical company developing psychedelic-based medications for the treatment of mental disorders. This is a new and rapidly developing field. The company's growth is driven not by economics, but by scientific breakthroughs and regulatory changes. It represents the vanguard of medicine, shaping the future job market in this field.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Silo Pharma Inc. (SILO)
Silo Pharma is a biotech company researching the use of psychedelics (such as ketamine and psilocybin) to treat neurological disorders. This chart shows the speculative market value of their R&D. It reflects the value of their IP in this cutting-edge but risky field per scientist.
%20of%20the%20company%20Silo%20Pharma%20Inc.%20(SILO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Silo-Pharma-Inc.-SILO&v=1772678615413 "Chart of market capitalization per employee (in thousands of dollars) of the company Silo Pharma Inc. (SILO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Silo Pharma (SILO) is a biopharmaceutical company developing new therapeutics based on psychedelics. In this cutting-edge and controversial field, this chart reflects investors' faith in changing legislation and medical paradigms. The high valuation per employee reflects a bet that psychedelics will become legal and effective medicines.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772678615456 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Silo Pharma is a biopharmaceutical company developing psychedelic-based drugs for the treatment of mental disorders. Its valuation is based on future potential. The chart shows a high cost per employee, as investors believe in the breakthrough nature of this research and the potential to create a new class of drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772678615519 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Silo Pharma Inc. (SILO)
Silo Pharma is a biotech company in the R&D phase developing psychedelic drugs for the treatment of neurological disorders (such as Parkinson's disease). This graph shows the net loss per employee, reflecting the fact that every scientist at the company represents an investment in time-consuming and expensive research and clinical trials.
%20Chart%20Silo%20Pharma%20Inc.%20(SILO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Silo-Pharma-Inc.-SILO&v=1772678615694 "Company Profit Per Employee (in thousands of dollars) Chart Silo Pharma Inc. (SILO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Silo Pharma, Inc. develops new therapeutics, including psychedelics, for the treatment of neurological disorders. In this cutting-edge field of pharmaceuticals, team performance is determined by the speed of research. The graph shows the financial return per employee, allowing us to assess the company's progress toward creating innovative drugs.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772678615756 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Silo Pharma is a biotech company focused on psychedelic medicine. They are developing treatments (such as ketamine) for PTSD, depression, and Alzheimer's disease. This is an R&D business. This chart, showing average profitability, helps to understand the contrast with biotech, where a team of scientists burns through capital in hopes of drug approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772678615931 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Silo Pharma Inc. (SILO)
Silo Pharma is a biopharmaceutical company working on psychedelic drugs. There is no revenue per employee during the research phase. The graph is important as an indicator of the company's enormous potential: if legalized and approved, these drugs could create a multibillion-dollar market, leading to explosive growth.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Silo-Pharma-Inc.-SILO&v=1772678615963 "Sales chart per company employee Silo Pharma Inc. (SILO)")
Sales per employee in the market segment - Pharma psycho
Silo Pharma is an early-stage (preclinical) biotech focused on developing psychedelic drugs (e.g., psilocybin) for the treatment of neurological disorders (PTSD, Parkinson's disease). They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of SILO's R&D staffing costs.
Sales per employee for the market as a whole
Silo Pharma is a biotech company focused on developing psychedelic drugs for the treatment of neurological disorders such as Parkinson's disease. At this stage, their business is focused on R&D. This graph reflects their pre-commercial stage, when the team's entire scientific resources are devoted to research.
Short shares by company, segment and market as a whole
Shares shorted by company Silo Pharma Inc. (SILO)
Silo Pharma (SILO) is a biotech company researching psychedelics (such as psilocybin) for the treatment of neurological disorders. This chart shows the volume of bearish bets. This is a highly hyped but legally and clinically complex sector. Bears are betting that the company will fail to pass regulatory hurdles.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Silo-Pharma-Inc.-SILO&v=1772678616061 "Short Shares Chart for the Company Silo Pharma Inc. (SILO)")
Shares shorted by market segment - Pharma psycho
Silo Pharma (SILO) is an early-stage biotech company focused on developing new treatments using psychedelics (such as psilocybin) for neurological disorders. This chart aggregates short positions across the biotech sector. It reflects investor skepticism about the psychedelic segment.
Shares shorted by the overall market
Silo Pharma operates in the highly speculative market for medical psychedelics. This chart measures the overall level of fear. When pessimism runs high, investors flee the hype. Shares of companies whose business involves R&D, with its enormous regulatory and scientific risks, are the first to sell off, as the market demands a safe haven.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Silo Pharma Inc. (SILO)
Silo Pharma operates in the speculative medical psychedelics sector. This chart is a pure indicator of hype. It shows how investor sentiment spikes on news of decriminalization or successful trials, and how quickly it cools due to regulatory barriers, reflecting the sector's volatility.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Silo-Pharma-Inc.-SILO&v=1772678616142 "RSI 14 indicator chart for the company's stock Silo Pharma Inc. (SILO)")
RSI 14 Market Segment - Pharma psycho
Silo Pharma (SILO) is a biotech company researching the use of psychedelics (ketamine, psilocybin) to treat neurological disorders. It's one of the most speculative sectors. This chart tracks the collective hype in the Psychedelics sector. It shows when the entire industry is overheated by legalization news or oversold by setbacks.
RSI 14 for the overall market
For Silo Pharma, which operates in the psychedelic space, this chart is an indicator of appetite for hype. During periods of market euphoria, investors are willing to generously fund speculative R&D projects for the "future." During moments of panic, capital flees unprofitable, "conceptual" projects, and companies risk running out of research funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SILO (Silo Pharma Inc.)
Silo Pharma is an early-stage biotech focused on developing new treatments (including psychedelics like psilocybin) for PTSD and Alzheimer's disease. This chart shows the highly speculative average price target from analysts based on their confidence in this R&D pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SILO-Silo-Pharma-Inc.&v=1772678616276 "A chart showing analyst consensus forecasts for the expected stock price. SILO (Silo Pharma Inc.)")
The difference between the consensus estimate and the actual stock price SILO (Silo Pharma Inc.)
Silo Pharma is a biotech company researching psychedelics (ketamine, psilocybin) to develop new treatments for mental disorders (depression, PTSD). This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their view on this revolutionary but risky R&D project.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SILO-Silo-Pharma-Inc.&v=1772678616299 "A chart showing the difference between the consensus forecast and the actual stock price. SILO (Silo Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Silo Pharma (SILO) is a "new breed" biotech company that licenses psychedelic drugs (psilocybin, DMT) from universities to treat neurological disorders. This chart shows general expectations for the psychopharma sector, reflecting whether experts believe in the medical potential of psychedelics.
Analysts' consensus forecast for the overall market share price
Silo Pharma is a biotech company operating in the psychedelic medicine sector. They are developing drugs (based on ketamine and psilocybin) for the treatment of PTSD and depression. This chart shows the overall market "risk appetite." For Silo, operating in a speculative and not yet fully legalized sector, overall market optimism (risk appetite) is critical for funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Silo Pharma Inc.
Silo Pharma is a biotech incubator for psychedelics. They don't do their own R&D; their business is identifying and funding (in partnership with universities) early-stage R&D projects using psychedelics (psilocybin, DMT) to treat neurological disorders. This chart is a pure indicator of their R&D portfolio, reflecting their (very risky) bets on alternative medicine.
AKIMA Market Segment Index - Pharma psycho
Silo Pharma (SILO) is a biopharmaceutical company operating at the intersection of psychedelics and R&D. They don't produce the compounds themselves, but rather develop innovative delivery methods (nasal and transdermal) for the treatment of PTSD, depression, and Alzheimer's disease. This chart shows the average index for the segment, helping to assess how this delivery strategy compares to the industry average.
The AKIM Index for the overall market
Silo Pharma is a biotech company developing treatments for stress and pain using psychedelics and traditional pharmacology. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends.
